Skip to main content
Premium Trial:

Request an Annual Quote

Biosimilars: A Fancy Name for Generics But Oh So Much More Disastrous

Over on VentureBeat, David Hamilton writes that even normally smart biotechnology investors get a little dim when talking about biosimilars and the loss of patent protection for biotech drugs. Steve Burrill, CEO of the life science venture capital firm Burrill & Company, told Fortune magazine that the approval of biosimilars will be "devastating for the industry." Hamilton responds that "if the biotech industry is so delicate that it requires perpetual protection from the cold, cruel winds of competition, it can’t possibly be anywhere near as innovative and revolutionary as it has always claimed."

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.